dpp4 and glp 1 combination glp-1 receptor agonist dpp-4 inhibitor not recommended versus kidney and cardiovascular outcomes in clinical practice in type-2 diabetes Frontiers dpp 4 inhibitors vs glp

Dr Shendy Engelina Consultant Dermatologist and Clinical Service Lead at Dermatica

This organ distribution difference enables the brain, kidneys and small intestines to sequester GSH from the blood circulation to meet the need of these organs for GSH, and provide a solid foundation for developing organ selective agents for these organs in general

While drug chemistry suggests low exposure, uncertainty remains

Med Sci Monit 23:54105419 Sun HX, Lu N, Luo X, Zhao L, Liu JM (2015) Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats

Erring on the side of caution with periodic assessment provides peace of mind and early warning of any unexpected effects